欧洲杯竞猜

      1. Home
        Who We Are
        What We Do
        Corporate Responsibility
        News
        Careers
        Investors
        Patients and HCPS
        Contact us
        Careers | Investors | Patients and HCPS | Contact us
        Global
        中文站
        Careers Investors Patients and HCPS Contact us
        Home / Company News / New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes Association’s 81st Scientific Sessions
        New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes Association’s 81st Scientific Sessions
        Date:2021-07-02

        Beijing, China/Bridgewater, New Jersey U.S, July 2, 2021 Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), announced positive Phase 1 clinical trial results at the 81st Scientific Sessions of the American Diabetes Association (ADA), June 25th – 29th. The new data pertained to three proposed biosimilar Gan & Lee insulin analogs, insulin aspart (GL-ASP), insulin lispro (GL-LIS), and insulin glargine (GL-GLA), and were presented by the primary investigators from Profil, (Germany).

         

        All three phase 1 studies met their primary PK and primary PD analyses. These data demonstrate pharmacokinetic and pharmacodynamic bioequivalence between each of the proposed biosimilar Gan & Lee insulins and their respective reference compounds. In addition, the safety profiles were comparable between each of the three proposed biosimilar Gan & Lee insulins and their respective reference compounds1,2,3.  

         

        The data presented from the abstracts, are a major milestone in the biosimilar clinical development programs at Gan & Lee. Although 2021 marks the centenary of insulin’s discovery, insulin access remains a global health issue. “We are excited as we move one step closer to bringing biosimilar insulins into clinical practice with a goal of helping reduce the global burden of diabetes,” said Jia Lu, Executive Director of Clinical Sciences. The three abstracts have recently been published on the journal Diabetes website and the poster presentation numbers for the GL-ASP, GL-LIS, and GL-GLA abstracts are 738-P, 736-P, and 740-P, respectively.

         

        About Gan & Lee

        Gan & Lee has successfully developed the first domestic biosynthetic human insulin in China. Currently, the company has five recombinant insulin analogs and other products commercialized in China including long-acting glargine injection (Basalin), fast-acting lispro injection (Prandilin), fast-acting aspart injection (Rapilin), mixed protamine zinc lispro injection (25R) (Prandilin25) and aspart 30 injection (Rapilin30), reusable insulin injection pen (GanleePen), and disposable pen needle (Ganlee Fine).

         

        Moving forward, Gan & Lee strives to advance its goal of becoming a world-class pharmaceutical company by providing a comprehensive coverage in the field of diabetes diagnosis and treatment, and also taking an active part in developing new chemical entities for the treatment of cardiovascular diseases, metabolic diseases, cancer, and other diseases.


        References

        1. Leona Plum- Mrschel, et. al. Proposed biosimilar insulin aspart (GL-ASP) shows pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin aspart. June 22, 2021.

        2. Eric Zijlstra, et. al. Proposed biosimilar insulin lispro (GL-LIS) shows pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin lispro. June 22, 2021.

        3. Tim Heise, et. al. Proposed biosimilar insulin glargine (GL-GLA) shows pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin glargine. June 22, 2021.



        Copyright 2021 Gan & Lee Pharmaceuticals Co Ltd . All Rights Reserved.
        Our websites

        Subscribe

        I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.

        欧洲杯竞猜